Y-mAbs Therapeutics Inc (OQ:YMAB)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 230 PARK AVENUE, SUITE 3350
NEW YORK NY 10169
Tel: N/A
Website: https://www.ymabs.com
IR: See website
<
Key People
Michael Rossi
President, Chief Executive Officer, Director
Thomas Gad
Vice Chairman of the Board, Chief Business Officer
Bo Kruse
Chief Financial Officer, Executive Vice President, Treasurer, Secretary
Joris Wiel Jan Wilms
Chief Operating Officer, Senior Vice President
Torben Lund-Hansen
Senior Vice President, Chief Technical Officer
Steen Lisby
Senior Vice President, Chief Scientific Officer
Vignesh Rajah
Senior Vice President, Chief Medical Officer
Susan Smith
Senior Vice President, Chief Commercial Officer
 
Business Overview
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
Financial Overview
For the fiscal year ended 31 December 2023, Y-mAbs Therapeutics Inc revenues increased 30% to $84.8M. Net loss decreased 78% to $21.4M. Revenues reflect License revenue increase of 71% to $84.3M. Lower net loss reflects Therapeutic products segment loss decrease of 73% to $25.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.19 to -$0.49.
Employees: 100 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $590.71M as of Dec 31, 2023
Annual revenue (TTM): $84.82M as of Dec 31, 2023
EBITDA (TTM): -$20.46M as of Dec 31, 2023
Net annual income (TTM): -$21.43M as of Dec 31, 2023
Free cash flow (TTM): -$27.23M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 43,777,105 as of Feb 22, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.